Pengbatasan Merokok di Kasino Missouri Lembap, Pengbatasan di Kansas Sudah Gagal iGame

Pengbatasan Merokok di Kasino Missouri Lembap, Pengbatasan di Kansas Sudah Gagal

March 27, 2026
(AsiaGameHub) - Merokok masih dibenarkan di seluruh 13 lantai perjudian kasino di Missouri, dan ahli parlimen sekali lagi telah memperkenalkan House Bill 1618 di Dewan Undangan Negeri negeri itu yang bertujuan untuk memaksa kasino menyediakan persekitaran bebas asap rokok. Walau bagaimanapun, tarikh akhir perundangan semakin hampir, jadi adalah sangat mungkin bahawa rang undang-undang itu tidak mempunyai cukup masa untuk diluluskan. Di samping itu, rang undang-undang serupa di Kansas telah gagal, walaupun ramalan sebelum ini mengatakan ia akan ditandatangani sebagai undang-undang. Larangan Merokok di Kasino Missouri Terperangkap dalam Perbincangan yang Tidak Berkesudahan Tetapi kembali ke Missouri – negeri itu kini membenarkan merokok di dalam ruangan kasino berkat pengecualian khas dalam 1993 Clean Indoor Air Law negeri. Walau bagaimanapun, House Bill 1618 (HB1618) bertujuan untuk menyemak semula dengan menghapuskan pengecualian itu. Cadangan itu masih menghadapi jalan yang panjang ke hadapan, terutamanya apabila badan perundangan di Jefferson City menghampiri penutupan untuk 2026. Menariknya, keadaan nampaknya lebih positif untuk HB1618 pada awal tahun ini, kerana ia telah diperkenalkan dengan sokongan dua parti. Langkah itu, yang ditulis oleh Ahli Dewan Negeri Rep. Bruce Sassmann (R-Montgomery), dianjurkan bersama oleh dua rakan Republikan dan empat Demokrat. Rang undang-undang itu menerima dua bacaan di dewan Dewan Undangan pada Januari tetapi masih belum diberikan kepada jawatankuasa untuk pertimbangan awal. Walau bagaimanapun, dengan Missouri General Assembly akan menutup pada 15 Mei, peluang untuk menghentikan merokok di kasino tahun ini kelihatan tipis, kerana masa mungkin habis. Satu sebab mengapa perbincangan mengenai HB 1618 kelihatan ketinggalan adalah isu lain yang berkaitan dengan perjudian yang dibincangkan oleh ahli parlimen dalam minggu-minggu terakhir. Contohnya, baru minggu lepas, undang-undang baru untuk mengawal mesin slot hampir diluluskan oleh Dewan Undangan. Ini adalah sebahagian daripada usaha lebih luas oleh negeri untuk mengawal permainan slot “pasar kelabu”. Malah, Peguam Negara Missouri Catherine Hanaway telah mula menyasarkan mesin perjudian haram, khususnya pada terminal loteri video (VLTs) yang sebelumnya beroperasi di kawasan undang-undang kelabu. Rang Undang-Undang Anti-Merokok di Kansas Gagal Sementara itu, di negeri jiran Kansas, Senate Bill 176, yang bertujuan untuk meminda Kansas Clean Air Act 2010 untuk membersihkan asap rokok kedua tangan dari empat kasino negeri itu, telah gagal. Kansas Senate Bill 176 telah kekal tidak aktif sejak Februari selepas dirujuk kepada Senate Committee on Federal and State Affairs, yang menyusun langkah itu atas permintaan Ahli Dewan Negara Sen. Mike Thompson (R-Johnson). Langkah pendamping di Kansas House of Representatives, yang disokong oleh Casino Employees Against Smoking Effects, juga telah terhenti. House Bill 2252 telah diletakkan selama berminggu-minggu di House Committee on Health and Human Services tanpa sebarang tindakan. Dewan Undangan Kansas tidak akan menutup sehingga 10 April. Walau bagaimanapun, SB176 dan HB2252 kini sudah tidak berdaya kerana mereka gagal untuk berpindah ke dewan lain sebelum hari crossover negeri itu, yang berlaku pada 19 Februari. Artikel ini disediakan oleh penyedia kandungan pihak ketiga. AsiaGameHub (https://asiagamehub.com/) tidak memberikan sebarang jaminan atau representasi berkaitan kandungannya. Kategori: Berita Terkini, Kemas Kini Umum AsiaGameHub menyediakan perkhidmatan pengedaran iGaming yang disasarkan untuk syarikat dan organisasi, dengan menghubungkan lebih daripada 3,000 media premium di Asia serta lebih 80,000 influencer khusus. Ia berfungsi sebagai jambatan utama untuk pengedaran kandungan iGaming, kasino, dan eSports di seluruh rantau ASEAN.
More
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint ACN Newswire

Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint

March 27, 2026
HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong, Macao and Taiwan region.Under the terms of the agreement, Everest will pay CORXEL an upfront payment of US$30 million (equivalent to approximately RMB344,895,000), as well as potential development milestone payments of up to US$20 million (equivalent to approximately RMB137,958,000). As part of this agreement, Everest will be assigned and transferred rights, interests, claims, duties, obligations and liabilities (other than certain excluded liabilities) under the Milestone License Agreement entered into by CORXEL in May 2021 and certain related ancillary agreements.CARDAMYST™ (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker as administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As a rapid-acting treatment option, CARDAMYST can be self-administered outside the emergency department or other healthcare settings, enabling patients to actively manage episodes and gain greater control over their condition. In addition to its approved indication for PSVT, etripamil nasal spray is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials have shown encouraging results, and Phase III trials are planned, with the potential to further extend its therapeutic impact to a broader patient population.In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025 and is expected to receive approval in the third quarter of 2026.PSVT is characterized by abnormalities in the heart's electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.AFib-RVR is a type of irregular heart rhythm, characterized by an irregular and elevated heart rate. Its onset is typically gradual, episodes are less likely to terminate spontaneously, and the condition tends to recur, significantly increasing the risk of thromboembolism and serious complications such as stroke and heart failure. In China, atrial fibrillation affects an estimated 1.6% of the population, representing nearly 20 million patients, and is expected to increase with an aging population. Both PSVT and AFib-RVR are associated with a loss of control and a significant psychological burden for patients.Overall, the combined patient population for PSVT and AFib-RVR exceeds 25 million, representing a significantly unmet clinical need that urgently requires more convenient and more effective treatment options.In terms of clinical data, the NDA for etripamil nasal spray was accepted by the NMPA based on data from the pivotal global Phase 3 RAPID study and the China Phase 3 JX02002 study. Both trials met their primary endpoints. Overall, the treatment emergent adverse events (TEAEs) were comparable between the etripamil and placebo groups. The FDA approval of CARDAMYST was supported by a robust clinical program that included safety data from more than 1,800 participants across more than 2,000 PSVT episodes. This included the Phase 3 RAPID trial, a global, randomized, double-blind comparison of etripamil versus placebo, published in The Lancet in 2023. The RAPID trial achieved its primary endpoint, with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared with 31% on placebo (N=85) (HR = 2.62; p
More
WSOP Bersiap Untuk Kembali di ESPN Sekali Lagi iGame

WSOP Bersiap Untuk Kembali di ESPN Sekali Lagi

March 27, 2026
(AsiaGameHub) - World Series of Poker, kuasa poker yang diasaskan oleh Benny Binion, dan ESPN telah mengesahkan perjanjian penstriman baharu pada hari Khamis, yang akan menyaksikan acara poker paling berprestij dan popular di dunia kembali di rangkaian penyiaran. ESPN Akan Membawa Aksi Poker Terbaik kepada Peminat Perikatan penstriman pelbagai tahun ini akan bermula dengan edisi acara tahun ini, yang dijadualkan bermula pada 2 Julai, 2026, dan akan berlangsung sehingga meja akhir, yang akan diadakan dari 3 Ogos hingga 5 Ogos, 2026. Butiran perjanjian telah dikongsikan, dengan liputan tiga meja berjalan serentak, khusus untuk Main Event, yang boleh dikatakan paling menyeronokkan dan berbaloi daripada pertandingan dalam jadual. Mengulas mengenai pencapaian penting ini, Ty Stewart, Ketua Pegawai Eksekutif World Series of Poker, mengalu-alukan perkembangan ini sebagai cara yang hebat untuk membawa pengalaman tontonan yang lebih pantas kepada peminat poker. “Dengan bangganya WSOP pulang ke ESPN. Warisan perkongsian ini membantu permainan ini meletup, dan kami tidak sabar untuk menyampaikan inspirasi melalui kandungan bertaraf dunia kepada generasi penonton baharu,” Stewart. WSOP Main Event menjanjikan untuk menjadi salah satu yang paling penting dalam sejarah, selepas edisi tahun lepas menyaksikan jumlah keseluruhan hadiah $90.5 juta yang dimungkinkan oleh lebih daripada 9,735 pemain. Ia adalah Main Event ketiga terbesar dalam sejarah siri itu, tetapi Stewart yakin bahawa acara itu masih belum memecahkan semua rekod. Walau bagaimanapun, sekatan perjalanan dari luar negara di bawah pentadbiran Trump mungkin telah memburukkan lagi iklim untuk pemain kelahiran asing dan pelawat. Sementara itu, WSOP terus menjadi jenama yang relevan secara budaya, dengan pelbagai perkara berlaku di sekelilingnya. Sebagai contoh, Phil Hellmuth, pemegang 17 gelang WSOP, baru-baru ini berkongsi pendapatnya bahawa bilangan gelang yang dianugerahkan setiap tahun harus dikurangkan. Beliau berhujah bahawa dengan memperkenalkan lebih banyak acara ini, nilai gelang asal semakin berkurangan. Artikel ini disediakan oleh penyedia kandungan pihak ketiga. AsiaGameHub (https://asiagamehub.com/) tidak memberikan sebarang jaminan atau representasi berkaitan kandungannya. Kategori: Berita Terkini, Kemas Kini Umum AsiaGameHub menyediakan perkhidmatan pengedaran iGaming yang disasarkan untuk syarikat dan organisasi, dengan menghubungkan lebih daripada 3,000 media premium di Asia serta lebih 80,000 influencer khusus. Ia berfungsi sebagai jambatan utama untuk pengedaran kandungan iGaming, kasino, dan eSports di seluruh rantau ASEAN.
More
Xunce Technology’s Revenue Surges 449% Half-on-Half: Is a Structural Revaluation to a Hundred-Billion Market Cap Camp on the Horizon? ACN Newswire

Xunce Technology’s Revenue Surges 449% Half-on-Half: Is a Structural Revaluation to a Hundred-Billion Market Cap Camp on the Horizon?

March 27, 2026
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB 484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector. Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
FA CHAI Gaming receives two award nominations at SiGMA South America 2026 iGame

FA CHAI Gaming receives two award nominations at SiGMA South America 2026

March 27, 2026
(AsiaGameHub) - This double nomination underscores FA CHAI Gaming’s swift global growth and dedication to innovation, as the studio seeks to transform industry acclaim at SiGMA South America 2026 into a landmark win alongside its expanding community of players and partners. Press release.- FA CHAI Gaming has earned nominations for both Best Game Studio 2026 and Best Slot Game Provider 2026 at SiGMA South America, acknowledging a trajectory marked by over 70 original titles, expansion into 100+ global markets, and player-centric experiences fueled by innovation, quality, and trust. As the company said, “This achievement honors not only the studio but also the community of players and partners who have supported us in reaching this point!” From one game to a global presence Since its founding, FA CHAI Gaming has centered its efforts on crafting not merely games, but a globally recognized content ecosystem. Boasting over 70 original titles spanning slots, fishing, arcade, and table games, the studio continues to grow its reach across more than 100 markets globally. Building games that last Titles such as SUGAR BANG BANG develop from standalone releases into multi-title franchises, demonstrating the studio’s capacity to turn successful ideas into enduring IP ecosystems. Designed for global players Featuring support for multiple languages and culturally adaptable themes, our games connect with audiences across regions while upholding a unified brand identity. Beyond gameplay: a connected ecosystem Via the Player Achievement System, Event Function, and FA CHAI Card, gameplay expands into a more comprehensive experience — fostering engagement, progression, and exploration across different titles. Powered by certified technology All products are constructed using advanced HTML5 architecture and certified by globally recognized laboratories, guaranteeing fairness, stability, and smooth performance across devices. From nomination to winning — together Earning a nomination is a significant milestone, yet the journey persists. Our goal is to take the next step: converting this nomination into a win. Q&A – FA CHAI Gaming & SiGMA South America 2026 What nominations has FA CHAI Gaming received? We are proud to have been nominated for Best Game Studio 2026 and Best Slot Game Provider 2026, recognizing our work in game innovation, content excellence, and global market expansion. What does this nomination mean for players and partners? This nomination represents international acknowledgment of our games and services. It motivates us to keep providing high-quality, player-focused experiences, while our partners gain from our growing global market reach and sustainable gaming ecosystem. What are the key features of FA CHAI Gaming’s games? Our games offer support for multiple languages and culturally adaptable themes, and through the Player Achievement System, Event Function, and FA CHAI Card, they form a full-fledged ecosystem that extends gameplay to include cross-title interactions and achievement tracking. How can I vote to support FA CHAI Gaming? Kindly visit the SiGMA South America 2026 voting page. Each vote aids us in converting our nomination into an award. What are FA CHAI Gaming’s plans for the future? We will continue to expand in global markets, develop original IP series, and innovate in player engagement, ensuring that every player enjoys a comprehensive and fulfilling gaming journey. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy JCN Newswire

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

March 27, 2026
TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG® (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.This application is based on the results of the Phase 3 LITESPARK-011 trial evaluating the dual regimen of LENVIMA plus WELIREG for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. The data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in February 2026. At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), the LENVIMA plus WELIREG combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the primary endpoints, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. The safety profile of this combination was consistent with those reported for each agent administered as monotherapy, and no new safety signals were identified.In 2022, approximately 435,000 people worldwide were newly diagnosed with kidney cancer, and about 156,000 people died from the disease. 1 In Japan, it is estimated that roughly 21,000 people were newly diagnosed and about 7,000 died in 2022.2 RCC accounts for approximately 85% of kidney cancers3, and the five-year survival rates for patients with stage III and IV RCC have been reported as 63%–78% and 27%–28%4, respectively, indicating that the disease still has a high unmet medical needs.LENVIMA is approved in combination with KEYTRUDA ® (pembrolizumab) in Japan for the first-line treatment of unresectable or metastatic RCC. WELIREG is approved in Japan for the treatment of unresectable or metastatic RCC that has progressed following cancer chemotherapy. Additionally, supplemental New Drug Applications (sNDA) for the LENVIMA and WELIREG combination therapy for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PDL1 inhibitor has been accepted by the U.S. Food and Drug Administration (FDA), with a PDUFA (Prescription Drug User Fee Act) target action date set for October 4, 2026.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution to patients with cancer.About LENVIMA (lenvatinib)LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1- 4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia) The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About WELIREG (belzutifan)WELIREG, Merck & Co., Inc., Rahway, NJ, USA’s, known as MSD outside of the United States and Canada, first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival. WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) diseaseassociated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond. WELIREG has been approved in Japan for the treatment of certain von Hippel–Lindau (VHL) disease–associated tumors, as well as for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.LITESPARK-011 ResultsData from LITESPARK-011 (ClinicalTrials.gov, NCT04586231) were presented at the ASCO GU Symposium held in February 2026. LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR), and overall survival (OS). Secondary endpoints include objective response rate (ORR) per RECIST v1.1 as assessed by BICR, duration of response (DOR) per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).At a pre-specified second interim analysis with a median follow-up of 29.0 months (range, 19.3- 49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0-31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol. Regarding secondary endpoints, at the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib. WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.6. About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncologyAbout MSDAt MSD (the name by which Merck & Co., Inc., Rahway, NJ, USA, is known outside of the United States and Canada), we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.co.jp and connect with us on Facebook, Twitter, and YouTube.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf, accessed 27 Mar 2026.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/392-japan-fact-sheet.pdf, accessed 27 Mar 2026.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2025; 2026 Version 1. Rose TL and Kim WY. Renal cell carcinoma: a review. JAMA. 2024 Sep 24;332(12):1001– 10.Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120MSD K.K.Communications DivisionTatsuro MuraseTEL: +81 (0)70-8700-0112 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility JCN Newswire

Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility

March 27, 2026
TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on their collaboration launched in May 2024*1 and further developed as announced in May 2025*2 , NextGen combines Hitachi’s technology and operational expertise with MUFG’s financial capabilities to accelerate the transition to decarbonized mobility.*1 MUFG’s Business Co-Creation and Investment into UK Battery as a Service project by Hitachi ZeroCarbon May 2024*2 Hitachi ZeroCarbon and MUFG unite technology expertise with financial support to accelerate fleet electrification May 2025NextGen was initially validated through a UK pilot project with First Bus, where the parties collaborated via a special purpose vehicle (SPV) to support the procurement and operation of electrification assets under a Battery-as-a-Service model. This expanded MoU extends NextGen beyond battery-focused structures, enabling broader and more scalable deployment across additional markets outside the UK and across a wider range of asset classes. These include emobility assets such as electric vehicles and charging infrastructure, associated energy management systems, and potentially extending to energy hubs supporting industrial assets, power grids and data centers.Hitachi and MUFG Bank will also develop and scale SPV structures to finance decarbonized mobility assets for fleet and transport operators. This approach removes capital constraints and accelerates implementation, enabling operators to focus on their core transport services. From Hitachi’s side, the initiative is led by its Strategic SIB Business Unit, bringing together expertise from across Hitachi including Hitachi Energy, as ‘One Hitachi’. Hitachi will also provide managed services for asset performance and lifecycle optimization, supported by data-driven solutions from Hitachi ZeroCarbon. Through this initiative, Hitachi aims to further advance and streamline mobility and charging infrastructure operations by expanding HMAX by Hitachi, a suite of next-generation solutions that embodies Lumada 3.0, differentiated by deep domain knowledge and AI.Electrifying commercial transport at pace will require an unprecedented deployment of vehicles, charging and energy infrastructure - alongside innovative financing models to support it. Global investment in electrified transport reached around US$750 billion in 2024, making it the largest segment of the energy transition worldwide*3 - yet many fleet operators face limited access to capital and the operational complexity of transitioning at scale. Against this backdrop, Hitachi and MUFG Bank aim to expand NextGen as a repeatable model to accelerate implementation by combining structured asset financing with managed services and data-driven optimization.*3 Sources: BloombergNEF’s Energy transition Investment Trends 2025In demonstration of the expanded pipeline, Hitachi ZeroCarbon and MUFG Bank have also entered into an MoU with Boreal Norge AS and its subsidiary Boreal Buss AS, one of Norway’s primary transport operators, providing transport services across several counties and employing around 3,000 employees across its fleet, which includes over 850 buses and 35 ferries. The parties will explore how they can support Boreal’s transition planning, de-risk operations, optimize services and strengthen competitiveness as concessions evolve.Jun Taniguchi, Senior Vice President and Executive Officer, CEO of Strategic SIB Business Unit, at Hitachi, Ltd. said:“We are delighted to advance this partnership which combines Hitachi’s deep expertise in social infrastructure and digital technologies with MUFG Bank, Ltd.’s financial strength to accelerate the transition to a decarbonized society. By improving the performance of assets such as batteries and charging infrastructure through Hitachi’s digital services led by HMAX, we can truly help customers optimize the total cost of ownership. This partnership embodies our One Hitachi approach, leveraging our diverse capabilities across the Group to support our customers in achieving their net-zero ambitions.”Masakazu Osawa, Senior Managing Executive Officer Chief Executive, Japanese Corporate & Investment Banking Business Unit of MUFG Bank, Ltd., said:“Building on MUFG’s Business Co‑Creation and Investment approach, this collaboration with Hitachi aims to create value through strategic partnerships that improve society and the environment. For the global EV market, our focus is not only on strengthening Hitachi’s leading position in Battery as a Service, but also on fostering a holistic value chain — including second‑ life battery markets — that supports the acceleration of electric mobility and the achievement of 2050 net‑zero targets. Together with our partners, we are committed to co‑creating sustainable businesses that become a driving force for progress worldwide.”Nikolai Knudsmoen Utheim, Group CEO, Boreal Norge AS said:“Our priority has always been to deliver first-class transport services to our customers, whether that’s on the road, rail or over water. In exploring how we can unlock the power of electrified fleets, we can not only deliver more sustainable operations, but upgrade our infrastructure and thread technology across our entire business model for more efficient, smart transport and energy management.”About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About MUFGMitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.About BorealBoreal is a leading mobility provider, operating buses, fast ferries, passenger ferries and trams in Norway and Sweden. We remain firmly committed to our societal mission of encouraging more people to travel collectively. At the same time, we are more than public transport. As the only company operating buses, ferries, fast ferries, trams and tourism services, we deliver integrated mobility solutions and travel experiences. Although Boreal is a young company in name, its heritage extends back more than 150 years. The company has around 3,000 employees and is headquartered in Stavanger, Norway. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Analogue 2025 Annual Results Profit Attributable to Owners of the Company Increases 23.5% to HK$167.0 Million ACN Newswire

Analogue 2025 Annual Results Profit Attributable to Owners of the Company Increases 23.5% to HK$167.0 Million

March 27, 2026
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
DSTGAMING Secures Developer of the Year and Expo Stand Awards at SPiCE South Asia Eventus Awards 2026 iGame

DSTGAMING Secures Developer of the Year and Expo Stand Awards at SPiCE South Asia Eventus Awards 2026

March 27, 2026
(AsiaGameHub) - DSTGAMING has been awarded Developer of the Year 2026 and SPiCE-IEST EXPO Stand of the Year Award 2026 at the SPiCE South Asia Eventus Awards, honoring its platform excellence and impactful exhibition presence. Press release. — DSTGAMING has earned two accolades at the SPiCE South Asia Eventus Awards: the Developer of the Year Award 2026 and the SPiCE-IEST EXPO Stand of the Year Award 2026. These honors were presented as part of the SPiCE South Asia gathering, which brings together industry stakeholders from across the regional gaming sector. The Developer of the Year Award recognizes companies that demonstrate steady progress in platform development, system performance, and technological implementation within the igaming space. This recognition highlights DSTGAMING’s ongoing efforts to enhance its platform infrastructure, ensuring reliability, scalability, and adaptability across multiple market environments. Additionally, the SPiCE-IEST EXPO Stand of the Year Award reflects the company’s display and engagement at the exhibition, acknowledging the effectiveness of its booth design, brand visibility, and interactions with event participants. This recognition underscores the importance of a strong on-site presence in complementing technology-driven offerings. Industry awards such as those presented at SPiCE South Asia play a role in spotlighting organizations that contribute to both innovation and operational excellence within the gaming sector. Being recognized across both development and exhibition categories demonstrates a balanced approach to product delivery and industry engagement. The company stated: “These awards represent a significant milestone for DSTGAMING, reaffirming our continued involvement in international industry platforms while maintaining a focus on platform performance and professional presentation within the global igaming ecosystem.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
Dari Pendapanan Poker hingga 30 Toko: Kisah Pembuka Fat Shack iGame

Dari Pendapanan Poker hingga 30 Toko: Kisah Pembuka Fat Shack

March 27, 2026
(AsiaGameHub) - Tom Armenti, presiden dan ketua pegawai eksekutif Fat Shack Inc., memulakan perniagaannya selepas tamat kolej, dengan $5,000 yang telah dimenanginya bermain poker dalam talian. Harapannya pada masa itu sangat rendah, memandangkan kos pembinaan yang besar adalah antara $150,000 dan $200,000. “Saya Langsung Tidak Mampu Melakukannya” “Saya ingat berfikir, ‘Saya langsung tidak mampu melakukan ini,’” kata Armenti dalam satu temubual dengan Katherine Tangalakis-Lippert dari Business Insider. Daripada berputus asa, dia mencari jalan penyelesaian alternatif. Daripada membina sebuah restoran, dia meminjam satu menggunakan wang judinya. Pada 2010, dia melancarkan Fat Shack dengan beroperasi dari sebuah kedai bagel tempatan pada waktu malam, selepas ia ditutup untuk hari itu. Hari-hari awal adalah sukar, kerana dia tidak mempunyai ruang penyimpanan di tapak, jadi dia menyimpan bahan-bahan dalam peti sejuk di garajnya dan membawa masuk inventori yang cukup untuk setiap hari. Walaupun situasinya kurang daripada ideal, susunan pelik itu terbukti berjaya untuknya, apabila pelajar mula membuat pesanan, menyebarkan berita, dan membuat telefon berdering tanpa henti. Tidak lama selepas itu, dia memutuskan untuk memindahkan perniagaan itu ke Fort Collins, Colorado, memandangkan populasi pelajar di sana jauh lebih besar dan, pada 2011, membuka lokasi Fat Shack pertama yang lengkap. Kesan Shark Tank Perniagaan itu melonjak naik pada minggu pertama, dan lebih banyak pertumbuhan segera menyusul, mendorongnya untuk membuka lokasi kedua di Boulder bersama seorang rapat rapat. Francais percubaan itu juga berjaya, membuatkan kedua-dua rakan itu menyedari konsep itu boleh ditingkatkan. Menjelang 2015, mereka melancarkan lokasi francais rasmi pertama, selalunya diketuai oleh orang yang telah bekerja dalam perniagaan itu. Satu titik perubahan utama berlaku empat tahun kemudian, apabila syarikat itu muncul dalam Shark Tank, meraih perjanjian untuk pengasasnya dengan Mark Cuban untuk $250,000 sebagai pertukaran untuk 15% daripada syarikat. Disebabkan oleh pendedahan itu, jualan sekali lagi melonjak, pertanyaan membanjir masuk, dan syarikat itu berkembang dengan pesat, mencapai 30 lokasi dan menjana kira-kira $20 juta dalam hasil tahunan. Walaupun berjaya, industri restoran telah menjadi lebih mencabar, di tengah-tengah tabiat pengguna yang sentiasa berubah dan persaingan yang semakin meningkat, memaksa Fat Shack untuk membuat keputusan yang sukar: kekal setia kepada identitinya atau ikut arus dan menawarkan pilihan yang lebih sihat. Mereka memilih yang pertama. “Kami langsung tidak boleh mengubah diri kami sebagai jenama kesihatan,” kata Armenti. Rantaian mereka terus memilih nilai, meningkatkan saiz hidangan, dan mengekalkan harga yang stabil. Malah sekarang, pengasas itu masih terlibat secara langsung, sering bekerja di kedai bersama-sama kakitangan. Artikel ini disediakan oleh penyedia kandungan pihak ketiga. AsiaGameHub (https://asiagamehub.com/) tidak memberikan sebarang jaminan atau representasi berkaitan kandungannya. Kategori: Berita Terkini, Kemas Kini Umum AsiaGameHub menyediakan perkhidmatan pengedaran iGaming yang disasarkan untuk syarikat dan organisasi, dengan menghubungkan lebih daripada 3,000 media premium di Asia serta lebih 80,000 influencer khusus. Ia berfungsi sebagai jambatan utama untuk pengedaran kandungan iGaming, kasino, dan eSports di seluruh rantau ASEAN.
More
ARK Invest Bersama Kalshi untuk Mengeksplorasi Peluang Peramalan Baru iGame

ARK Invest Bersama Kalshi untuk Mengeksplorasi Peluang Peramalan Baru

March 27, 2026
(AsiaGameHub) - Perkongsian baharu antara Kalshi dan ARK Invest sedang mendorong platform ramalan ke arah pelaburan profesional arus perdana, kerana firma-firma mencari alat yang lebih baik untuk meramalkan masa depan yang semakin tidak pasti. Kerjasama ini akan menawarkan perspektif yang berbeza daripada kaedah ramalan tradisional, dengan memanfaatkan kebijaksanaan orang ramai untuk mengumpul isyarat yang sering terlepas oleh model tradisional. Pasaran Ramalan Boleh Menawarkan Pandangan Unik ARK merancang untuk menguji bagaimana isyarat tersebut sesuai dengan proses penyelidikannya. Firma ini, yang terkenal dengan penggunaan teknologi baru-baru ini, akan menggunakan pasaran ramalan untuk mengumpul lapisan maklumat tambahan, melengkapi alat sedia ada. Analis merancang untuk menjejaki kontrak yang berkaitan dengan penunjuk ekonomi dan perkembangan industri untuk mengenal pasti corak pelaburan yang akan membantu dalam membuat keputusan. Sebahagian daripada kerja ini telah dijalankan. ARK telah memantau pasaran Kalshi, seperti produktiviti dan defisit kerajaan persekutuan, dalam kajian awal. Penyelidik bertujuan untuk menentukan sama ada penentuan harga kebarangkalian dalam masa nyata boleh mengenal pasti titik perubahan dengan lebih cepat daripada analisis konvensional. Pergerakan harga yang berterusan berkaitan penunjuk ini mungkin membantu pelabur memantau jangkaan semasa dengan tepat. “Kami percaya isyarat ini boleh meningkatkan proses penyelidikan kami dan menyediakan konteks berharga mengenai pemacu utama dalam sektor-sektor yang mendisrupsi, membantu pelabur membuat keputusan yang lebih berpengetahuan.” Cathie Wood, pengasas, CEO, dan CIO ARK Invest Walau bagaimanapun, terdapat beberapa kebimbangan yang masih wujud. Likuiditi berbeza-beza merentasi kontrak, dan tidak semua pasaran menarik penyertaan yang mencukupi untuk menghasilkan isyarat yang boleh dipercayai. Tingkah laku orang ramai juga boleh mempengaruhi harga, terutamanya di kawasan yang kurang diperdagangkan. Walaupun begitu, arahnya jelas. Firma-firma seperti ARK kini menggunakan pasaran ramalan sebagai alat berharga untuk melengkapi model pendapatan dan ramalan ekonomi sedia ada mereka. Kalshi Berusaha untuk Memperoleh Penggunaan Aras Utama Penggunaan institusi seperti ini boleh menjadi keuntungan besar untuk kesahihan Kalshi sebagai platform kewangan arus perdana. Ia mengubah ketidakpastian dunia sebenar menjadi kontrak boleh diperdagangkan, dengan harga yang mencerminkan pertimbangan kolektif. Minat yang meningkat daripada pelabur profesional telah mengesahkan usaha Kalshi untuk mengembangkan cara pasaran dicipta dan diedarkan kerana syarikat itu bertujuan untuk menghantar produk yang matang dan mantap. “Apabila penggunaan pasaran ramalan oleh institusi meningkat, Kalshi melihat peningkatan permintaan untuk saluran permintaan pasaran formal untuk membantu pelabur memanfaatkan kebijaksanaan orang ramai.” Tarek Mansour, CEO Kalshi Perkongsian ARK ini mengikuti perjanjian serupa dengan Tradeweb Markets pada bulan Februari. Syarikat itu sedang menyepadukan data kebarangkalian Kalshi ke dalam ekosistem perdagangannya untuk melengkapi penunjuk yang lebih dikenali seperti kadar dan spread kredit. Penambahan ini akan memberi pengurus portfolio ukuran lain untuk menilai risiko yang mungkin dan membuat keputusan yang berpengetahuan. Bersama-sama, kedua-dua perjanjian menunjukkan bagaimana institusi telah mengubah pendekatan mereka terhadap maklumat. Sistem pasaran ramalan dengan cepat menjadi sebahagian daripada aliran kerja yang mapan yang mengendalikan modal sebenar dalam skala besar. Minat yang semakin meningkat ini menunjukkan keyakinan yang meningkat bahawa pasaran berasaskan kebarangkalian boleh menemui nuansa yang kadangkala terlepas daripada analisis tradisional. Artikel ini disediakan oleh penyedia kandungan pihak ketiga. AsiaGameHub (https://asiagamehub.com/) tidak memberikan sebarang jaminan atau representasi berkaitan kandungannya. Kategori: Berita Terkini, Kemas Kini Umum AsiaGameHub menyediakan perkhidmatan pengedaran iGaming yang disasarkan untuk syarikat dan organisasi, dengan menghubungkan lebih daripada 3,000 media premium di Asia serta lebih 80,000 influencer khusus. Ia berfungsi sebagai jambatan utama untuk pengedaran kandungan iGaming, kasino, dan eSports di seluruh rantau ASEAN.
More
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency JCN Newswire

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27, 2026
TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
New “L00 Series” Train for the Seibu Railway’s Yamaguchi Line Begins Commercial Operation JCN Newswire

New “L00 Series” Train for the Seibu Railway’s Yamaguchi Line Begins Commercial Operation

March 26, 2026
The Frst New Leo Liner "L00 Series"TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trainsets L00 Series ("Leo-kei") trains (4 cars per trainset, total 12 cars) ordered by Seibu Railway Co., Ltd. for its Yamaguchi Line, an automated guideway transit (AGT) system. Commercial operation of the first train began on March 27th. That same day, Seibu Railway held a commemorative ceremony for the start of commercial operation, attended by Tokorozawa City Mayor Masatoshi Onozuka and Higashimurayama City Mayor Takashi Watanabe.The new L00 Series are being manufactured at MHI's Mihara Machinery Works in Hiroshima Prefecture, and are scheduled to be delivered sequentially by FY2027. The seating arrangement has been changed from the bench seats used in the existing 8500 Series vehicles to longitudinal seats to increase transport capacity to BELLUNA DOME baseball stadium and Seibuen Amusement Park. To meet diverse passenger needs, wheelchair spaces, children's seats, and in-car information displays have been installed to enhance convenience.In addition, the new trains incorporate many unique specifications designed by MHI especially for AGT system vehicles, including aluminum bodyshells, the MHI bogie,(1), a ceiling duct air conditioning system,(2) and A-MVCS (Advanced Mitsubishi Vehicle Control System). The A-MVCS in particular, in addition to the vehicle control function, has monitoring and commissioning functions for each piece of on-board equipment, allowing it to flexibly meet the needs of railway operators.Further, a large glass window has been installed in the partition wall between the driver's cab and the children's seat, allowing children to enjoy the view from the front window and driver's seat, enhancing the sense of excitement for passengers.This AGT system utilizes rubber tires for a smooth ride and low noise. In addition, as a type of clean mobility with low CO2 emissions, the system has a reduced environmental impact, supporting the realization of a decarbonized and energy-efficient world. The adoption of vehicles that combine excellent design and environmental performance also enhances the impression of the surrounding facilities.Going forward, MHI Group will continue to strive for technological innovation, and through services that safely and comfortably transport people and goods, contribute to the development of public transport that supports the lives of people around the world.(1) A bogie developed by MHI for AGT systems. It is compatible with general rubber tire operation for AGTs.(2) A system that directs air through ducts behind the ceiling to provide air conditioning.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Modern Dental Group Announces 2025 Annual Results, Net Profit Surges 47.7% on Digitalization-Driven Operational Efficiency Gains ACN Newswire

Modern Dental Group Announces 2025 Annual Results, Net Profit Surges 47.7% on Digitalization-Driven Operational Efficiency Gains

March 26, 2026
RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Pembuat Undang-Undang New York Memajukan Langkah-Langkah untuk Mengurangkan Bahaya Perjudian iGame

Pembuat Undang-Undang New York Memajukan Langkah-Langkah untuk Mengurangkan Bahaya Perjudian

March 26, 2026
(AsiaGameHub) - The New York State Assembly telah meluluskan satu set luas langkah perundangan yang bertujuan untuk mengurangkan bahaya berkaitan perjudian dan memperkukuhkan perlindungan pengguna, memandangkan aktiviti pertaruhan terus berkembang di seluruh negeri. Rancangan Undang-undang Baru Bertujuan Meningkatkan Perlindungan Pemain dalam Sektor Pertaruhan yang Berkembang Inisiatif yang diketuai oleh Assembly Speaker Carl Heastie dan ahli Racing and Wagering Committee memperkenalkan beberapa pembaharuan yang direka untuk menggalakkan amalan perjudian bertanggungjawab di kalangan kasino dan pengendali pertaruhan mudah alih. Ahli perundangan menekankan bahawa pertumbuhan pesat pertaruhan sukan dalam talian telah mencipta risiko baru, menjadikan pengawasan yang lebih kukuh perlu dilakukan. Satu komponen utama dalam pakej ini menumpukan kepada memudahkan proses bagi individu yang ingin menjauhi perjudian. Di bawah perubahan yang dicadangkan, penduduk akan dapat menghantar permohonan pengecualian diri, menghapuskan keperluan untuk prosedur secara hadir dan merendahkan halangan bagi mereka yang cuba mengehadkan penyertaan mereka. Peruntukan tambahan bertujuan untuk memperketatkan keselamatan dan akauntabiliti bagi platform pertaruhan. Pengendali akan diwajibkan melaksanakan sistem pengesahan identiti yang lebih ketat dan memperkenalkan rangka kerja pemantauan risiko untuk mengesan tingkah laku pertaruhan yang berbahaya. Ahli perundangan percaya langkah perlindungan ini boleh membantu mengenal pasti tanda-tanda awal ketagihan dan mencegah peningkatan lebih lanjut. The New York State Assembly juga membincangkan peranan pengiklanan dalam aktiviti perjudian. Peraturan baru akan menyesuaikan standard pemasaran untuk buku sukan mudah alih dengan yang telah digunakan untuk kasino tradisional. Iklan video khususnya perlu memaparkan talian panas masalah perjudian sepanjang tempoh tayangan mereka, memastikan sumber sokongan kekal kelihatan kepada penonton pada semua masa. Langkah Baru Bertujuan Meningkatkan Akses Rawatan dan Kesedaran Pemain Satu lagi langkah penting menyasarkan akses kepada rawatan. Perundangan yang dicadangkan akan memerlukan skim insurans kesihatan komersial untuk menampung perkhidmatan luar rawatan untuk ketagihan perjudian. Ahli perundangan menyatakan bahawa liputan yang tidak konsisten telah menyebabkan ramai individu tidak mampu membayar rawatan, memaksa sesetengah mereka membayar kos sendiri yang tinggi atau meninggalkan rawatan. Untuk meningkatkan ketelusan, platform pertaruhan juga akan diwajibkan memberikan pengguna laporan aktiviti bulanan yang terperinci. Kenyataan ini akan termasuk data seperti deposit, penarikan, dan hasil pertaruhan keseluruhan, memberikan individu gambaran yang lebih jelas tentang tabiat perjudian mereka. Tambahan pula, pakej perundangan ini meminta penubuhan pasukan tugas bebas untuk meneliti pertaruhan cadangan, iaitu pertaruhan yang tidak berkaitan dengan hasil permainan. Pegawai kerajaan menyatakan kebimbangan bahawa pertaruhan sedemikian mungkin lebih terdedah kepada manipulasi dan boleh menimbulkan risiko kepada kedua-dua pengguna dan integriti pasaran. Sebagai sebahagian daripada usaha kesedaran yang lebih luas, The New York State Assembly juga telah bergerak untuk mengiktiraf Mac sebagai Problem Gambling Awareness Month di New York. Penyokong pakej ini mengatakan bahawa langkah-langkah tersebut mewujudkan keseimbangan antara menyokong industri yang berkembang dan melindungi kesihatan awam, dengan penekanan kuat pada pencegahan, ketelusan, dan akses kepada rawatan. Artikel ini disediakan oleh penyedia kandungan pihak ketiga. AsiaGameHub (https://asiagamehub.com/) tidak memberikan sebarang jaminan atau representasi berkaitan kandungannya. Kategori: Berita Terkini, Kemas Kini Umum AsiaGameHub menyediakan perkhidmatan pengedaran iGaming yang disasarkan untuk syarikat dan organisasi, dengan menghubungkan lebih daripada 3,000 media premium di Asia serta lebih 80,000 influencer khusus. Ia berfungsi sebagai jambatan utama untuk pengedaran kandungan iGaming, kasino, dan eSports di seluruh rantau ASEAN.
More
N1 SEO Traffic Cup: Increase your traffic exponentially and access luxury rewards iGame

N1 SEO Traffic Cup: Increase your traffic exponentially and access luxury rewards

March 26, 2026
(AsiaGameHub) - The N1 SEO Traffic Cup has reached its halfway point, with over 200 teams competing for luxury rewards and a flexible prize pool ahead of the tournament's conclusion on April 30. Press release.- The N1 SEO Traffic Cup, the first event in the global N1 Traffic Cups series by N1 Partners, is approaching its midpoint, with competition between teams intensifying. Participants are continuing to scale their volumes, refine their strategies, and actively add new brands to boost their N1 Cup Score and secure positions in the reward tiers. More than 200 teams remain in the competition, working to meet KPIs and gain participant status while aiming for the prize levels. Win big with N1 Partners The prize pool of the N1 SEO Traffic Cup is among the most extensive and flexible in the industry. Participants are grouped into performance-based tiers: the more points they earn, the greater the rewards, and each team can select a prize or its cash equivalent from their respective tier. Level 1 (7,000+ points) – €25,000 per team VIP experience at the Formula 1 Monaco Grand Prix Trip to a FIFA World Cup 2026 match in the USA 7 nights in the Maldives with business class flights Rolex Cosmograph Daytona BMW S 1000 XR motorbike Hublot Unico Titanium Level 2 (3,500–6,999 points) – €15,000 per team One week of golf at Monte Rei with a private villa stay Private island getaway in the Seychelles (Four Seasons Desroches Island) Ducati Monster motorbike Bottega Veneta travel kit Level 3 (1,500–3,499 points) – €7,000 per team Zero-gravity flight (90 minutes) Custom Luxury ski or snowboard gear set of your choice Balenciaga Snowboard Cartier Juste un Clou bracelet Kronos Massage Chair Level 4 (500–1,499 points) – €5,000 per team Apple Vision Pro MacBook Pro M4 Cartier LOVE ring Pioneer OPUS-QUAD DJ system Sonos Arc Ultra home audio system Dior beauty set Participant giveaways Even if a team doesn’t reach a reward tier, the opportunity doesn’t end there. Generating just 20 FTD on any brand unlocks participant status and access to a separate prize draw, featuring PlayStation 5 Pro, iPhone 17 Pro Max, and exclusive N1 Partners merch. This means you still have a real chance to win prizes, even with a late start or smaller volumes. How to increase your chances of winning The key tournament metric is the N1 Cup Score, calculated as: FTD × brand coefficient. The coefficient depends on how many brands you run: 1 brand – 1x 2–3 brands – 2x 4+ brands – 5x This means teams that diversify traffic across multiple products gain a strong strategic advantage and scale results much faster. Why join the race now The final stage of the tournament is not just about holding positions. It’s the perfect moment to rethink your strategy, test new approaches, and maximize the value of your current traffic. Late entry is no longer a limitation. With the right approach to brands and GEOs, teams can quickly scale FTD and break into the reward tiers. Join the N1 SEO Traffic Cup: https://n1.partners/traffic-cups?utm_campaign=media&utm_source=web&utm_medium=focusgn&utm_content=n1seotrafficcup_2ndreminder Period: March 1 – April 30, 2026 Results announcement: by May 10 Entry: from 20 FTD per brand N1 Partners means: 14+ casino and sportsbook brands with up to 70 per cent Reg2Dep 10+ Tier-1 GEOs CPA up to €700 and RevShare up to 45 per cent + NNCO for top partners Be number one with N1. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
JF SmartInvest Holdings Ltd Adjusted Profit Leaps 191.8% to RMB1.02 Billion ‘Technology + Investment Research’ Dual-Driver Strategy Delivers Remarkable Results, Overseas Expansion Ushers in a New Chapter of Globalisation ACN Newswire

JF SmartInvest Holdings Ltd Adjusted Profit Leaps 191.8% to RMB1.02 Billion ‘Technology + Investment Research’ Dual-Driver Strategy Delivers Remarkable Results, Overseas Expansion Ushers in a New Chapter of Globalisation

March 26, 2026
HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TaDaGaming signs new agreement in Brazil with Superbet iGame

TaDaGaming signs new agreement in Brazil with Superbet

March 26, 2026
(AsiaGameHub) - A forward-thinking content provider has formed a partnership with a cutting-edge operator. Press release.- TaDa Gaming is expanding its distinctive content to a broader audience in Brazil via its newest partnership with Superbet, the flagship brand of top-tier technology and entertainment firm, Super Technologies (Super). Under this new agreement, Superbet users will gain access to titles from the Lucky series such as Lucky Macaw (Arara da Sorte); Clover Coins 3×3 (Moedas da Sorte 3×3), and TriLuck games including 3 Witch's Lamp (3 Lãmpadas da Bruxa). The distribution is handled by Bragg. TaDa Gaming's specialized glocalisation approach and expertise in the Brazilian market has been continually strengthened viah prominent domestic and global casino collaborations since its debut. The consistent launch of slot and fish-shooting titles compliant with Law 14790 has further elevated TaDa Gaming's reputation throughout the nation for engaging, thrilling and secure gameplay. As a reputable, licensed and supervised content supplier with an extensive collection of over 230 games, all skillfully adapted for various markets, TaDa Gaming is also recognized for its customized gamification features GiftCode and WIN CARD, along with its newest offerings, Hot Hand and Highlights. Established in 2008, Super's objective is to provide thrilling, tech-driven amusement within the sports and gaming sectors. The firm presently maintains a significant business footprint throughout Europe and Latin America; and Super has strategically aligned itself to build the foundational framework that will power the forthcoming generation of entertainment experiences by collaborating with premier partners. Ray Lee, business development director at TaDa Gaming, commented: “TaDa Gaming is persistently advancing as an international enterprise to deliver increased value to collaborations and the sector as a whole. Partnering with a distinguished platform like Superbet provides us with additional impetus for expansion in Brazil. We anticipate the forthcoming developments.” Gavin Deadman, gaming head at Super Technologies, added: “The objectives of our flagship commercial brand, Superbet, are to attain market dominance by championing customer-focused approaches, create enduring long-term worth and contribute to molding the future of tech-fueled entertainment. Collaborating with a pioneering supplier like TaDa Gaming confirms our commitment to providing cutting-edge gaming experiences.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
How to Choose the Right Savings Account for Your Money Goals in Singapore ACN Newswire

How to Choose the Right Savings Account for Your Money Goals in Singapore

March 26, 2026
SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Rubio bertemu menteri G7 di Perancis ketika AS memimpin isu Iran — sekutu dikritik atas respons lemah kewangan

Rubio bertemu menteri G7 di Perancis ketika AS memimpin isu Iran — sekutu dikritik atas respons lemah

March 26, 2026
(SeaPRwire) - Setiausaha Negara Marco Rubio tiba di Perancis pada Jumaat untuk menghadiri mesyuarat menteri luar G7 di mana beliau akan menyampaikan mesej yang jelas mengenai keutamaan AS untuk perang yang sedang berlangsung dengan Iran.Dalam beberapa hari menjelang mesyuarat, ahli-ahli lain telah mengambil pendekatan yang berbeza secara ketara terhadap perang tersebut. Hampir semua rakan kongsi Washington — Britain, Kanada, Perancis, Jerman, Itali dan Jepun — telah bertindak berhati-hati terhadap kempen ketenteraan AS-Israel dan enggan menyertai operasi serangan, walaupun mereka mengutuk tindakan Iran.Sebelum berlepas pada Khamis, Rubio memberi isyarat pendekatan yang mencabar terhadap rundingan: "Saya tidak bekerja untuk Perancis atau Jerman atau Jepun… orang yang saya minati untuk menggembirakan ialah rakyat Amerika Syarikat. Saya bekerja untuk mereka," katanya dalam video yang disiarkan di X.Perbezaan itu telah menimbulkan kekecewaan daripada Presiden Donald Trump, yang telah mendesak sekutu untuk menyumbang lebih banyak, terutamanya dalam mengamankan laluan maritim utama seperti Selat Hormuz. Walaupun sesetengah negara telah memberi isyarat kesediaan untuk menyokong usaha pertahanan atau keselamatan maritim, mereka tidak menyertai serangan ketenteraan langsung."AS sentiasa diminta untuk membantu dalam peperangan dan kami telah melakukannya. Tetapi apabila kami mempunyai keperluan, kami tidak mendapat respons positif daripada NATO. Beberapa pemimpin berkata Iran bukanlah perang Eropah. Nah, Ukraine bukanlah perang kami, namun kami telah menyumbang lebih banyak kepada perjuangan itu daripada sesiapa pun," tambah Rubio."Selat Hormuz boleh dibuka esok jika Iran berhenti mengancam perkapalan global, yang merupakan satu penghinaan dan pelanggaran undang-undang antarabangsa. Bagi semua negara yang mengambil berat tentang undang-undang antarabangsa, mereka sepatutnya melakukan sesuatu mengenainya," katanya sebelum menaiki pesawatnya ke Perancis.Kenyataan itu menetapkan nada untuk sidang kemuncak yang sudah ditandai dengan geseran yang semakin meningkat antara Washington dan beberapa sekutu terdekatnya mengenai cara menangani konflik Iran. Rubio telah membingkaikan pertaruhan dalam istilah yang jelas. "Iran telah berperang dengan Amerika Syarikat selama 47 tahun… Iran telah membunuh rakyat Amerika dan menyerang rakyat Amerika di seluruh planet ini," katanya semasa mesyuarat kabinet Rumah Putih, sambil menambah bahawa membenarkan Tehran memperoleh senjata nuklear akan menjadi "risiko yang tidak boleh diterima oleh dunia."Tetapi walaupun sebelum Rubio tiba di mesyuarat, pegawai Eropah telah memberi isyarat pendekatan yang berbeza secara ketara."Kita perlu keluar daripada perang, bukan meningkatkannya lagi, kerana akibatnya kepada semua orang di seluruh dunia adalah sangat teruk," kata Naib Presiden Suruhanjaya Eropah Kaja Kallas semasa taklimat di luar G7 pada Khamis."Ia hanya boleh menjadi penyelesaian diplomatik… duduk dan berunding untuk mencari jalan keluar," tambahnya.Perbezaan antara bingkai Rubio dan mesej Kallas menangkap ketegangan teras yang membentuk mesyuarat itu.Pegawai AS berkata Rubio menuju ke rundingan dengan agenda yang lebih luas yang melangkaui Iran.Menurut jurucakap Jabatan Negara, yang bercakap dengan Digital secara latar belakang, Rubio akan menggunakan mesyuarat itu untuk "memajukan kepentingan utama AS" dan mendorong perbincangan mengenai perang di Ukraine dan Timur Tengah, serta "perkongsian beban antarabangsa" dan keberkesanan keseluruhan G7.AS juga dijangka menekankan keselamatan maritim, termasuk kebebasan navigasi di Selat Hormuz dan Laut Merah, sambil mendesak sekutu untuk memikul bahagian tanggungjawab yang lebih besar di zon konflik dan organisasi antarabangsa, kata jurucakap itu.Pegawai Eropah sebaliknya menekankan risiko yang lebih luas daripada konflik itu.Menteri luar Perancis, Jean-Noël Barrot, berkata perbincangan di G7 akan membina kenyataan bersama baru-baru ini yang mengutuk tindakan Iran sambil juga menangani kebimbangan keselamatan maritim.Beliau berkata "perbincangan akan memberi peluang untuk mengkaji semula kedudukan yang telah dipersetujui di peringkat G7… termasuk serangan yang tidak dapat dipertahankan yang dijalankan oleh Iran terhadap negara-negara Teluk… yang kami kutuk sekeras-kerasnya."Barrot menambah bahawa menteri-menteri juga akan memberi tumpuan kepada mengamankan laluan perkapalan global."Kami juga akan berpeluang untuk menangani keselamatan maritim dan kebebasan navigasi… termasuk misi antarabangsa… untuk memastikan kelancaran trafik maritim dalam postur yang sangat defensif, dengan itu membantu mengurangkan tekanan ke atas harga tenaga," katanya.Kallas menggemakan bingkai global itu. "Semua negara di dunia secara satu atau lain cara terjejas oleh perang ini… adalah kepentingan semua orang bahawa perang ini berhenti," katanya.Kenyataannya juga menunjukkan sifat saling berkaitan krisis itu. "Rusia membantu Iran dengan perisikan… dan juga menyokong Iran sekarang dengan dron," katanya, menghubungkan konflik Iran dengan perang di Ukraine.Ketidakpastian itu sudah menjejaskan struktur sidang kemuncak, dengan pegawai menggugurkan rancangan untuk komunike akhir yang bersatu untuk mengelakkan pendedahan perpecahan, lapor Reuters.Penganalisis berkata perbezaan itu mencerminkan ketegangan struktur yang lebih mendalam dalam pakatan itu. "Eropah telah mengkritik strategi 'tekanan maksimum' Donald Trump terhadap Iran sambil meneruskan pendekatan diplomatik yang gagal yang telah membolehkan rejim itu mengembangkan rangkaian pengganasnya dan menghampiri status ambang nuklear," kata Barak Seener, felo penyelidik kanan di Henry Jackson Society, kepada Digital."Ini mencerminkan kekurangan keupayaan Eropah untuk memproyeksikan kuasa di rantau ini, terutamanya dalam menjaga Selat Hormuz."Seener menambah bahawa bertahun-tahun bergantung kepada Washington telah meninggalkan Eropah semakin terdedah apabila AS mengubah keutamaan strategiknya. "Tahun-tahun pelaburan pertahanan yang rendah dan pergantungan kepada Amerika Syarikat telah mewujudkan pergantungan yang semakin dilihat oleh Washington sebagai pengkhianatan terhadap keamanan yang telah dijamin oleh AS kepada Eropah sejak Perang Dunia Kedua," katanya."Dengan AS memberi nilai yang lebih tinggi kepada hubungannya dengan Israel berbanding NATO, hasilnya mungkin adalah hakisan lanjut pakatan itu, pengurangan sokongan untuk Ukraine dan peningkatan tekanan ekonomi ke atas Eropah."Beliau memberi amaran bahawa ujian segera akan datang di G7 itu sendiri. "Perpecahan mengenai cara bertindak balas terhadap Iran dan sebarang permintaan AS untuk sokongan berkemungkinan mendedahkan perpecahan transatlantik yang lebih mendalam," kata Seener."Operasi Epic Fury telah mempamerkan keupayaan Presiden Trump untuk mengumpulkan gabungan sekutu untuk menghapuskan ancaman bersama — dalam kes ini rejim Iran — dan menstabilkan perdagangan antarabangsa," kata Jacob Olidort, ketua pegawai penyelidikan dan pengarah keselamatan Amerika di America First Policy Institute, kepada Digital."Kegagalan Eropah Barat untuk mengambil bahagian dalam mengamankan Selat Hormuz amatlah teruk kerana negara-negara itu bergantung kepadanya lebih daripada kami," tambahnya."Pada masa yang sama, kejayaan bersejarah Operasi Epic Fury telah membangkitkan keyakinan baharu dalam rakan kongsi Timur Tengah kami untuk membasmi ancaman daripada rejim Iran dan bekerja bersama untuk membentuk rantau yang lebih aman dan makmur."Artikel ini disediakan oleh pembekal kandungan pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberi sebarang waranti atau perwakilan berkaitan dengannya. Sektor: Top Story, Berita Harian SeaPRwire menyampaikan edaran siaran akhbar secara masa nyata untuk syarikat dan institusi, mencapai lebih daripada 6,500 kedai media, 86,000 penyunting dan wartawan, dan 3.5 juta desktop profesional di seluruh 90 negara. SeaPRwire menyokong pengedaran siaran akhbar dalam bahasa Inggeris, Korea, Jepun, Arab, Cina Ringkas, Cina Tradisional, Vietnam, Thai, Indonesia, Melayu, Jerman, Rusia, Perancis, Sepanyol, Portugis dan bahasa-bahasa lain.
More